Ser ikke så verst ut, solid tailwind fra biotech i usa i går for Genmab
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R 2 ) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting
- In the Phase 3 EPCORE ® FL-1 trial, fixed duration EPKINLY + R 2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R 2 , with approximately three out of four patients achieving a complete response
- This approval marks the third indication for EPKINLY and the first-ever FDA approval for a bispecific combination therapy in the lymphoma space
1 Like